baber/WOPTO huggingface dataset:
Patent MX-152135-A (MX)
Inventor: CREUTZ HANS-GERHARD
IPC: C25C3/22
Filed: 1979-01-16
Abstract: A non-cyanide acid or substantially neutral zinc electroplating bath and zinc plating process employing said bath which contains a brightening and leveling agent, and which comprises a bath soluble quaternary salt formed by the reaction of a heterocyclic compound with an alkylating agent comprising a dialkyl sulphate, an alkyl alkane sulphonate or an alkyl arene (e.g. toluene) sulphonate, or with an alkyl halide. The heterocyclic compound may be pyridine, (iso)quinoline, quinaldine, pyrimidine, phenazine, imidazole, imidazoline, pyrrole, pyrazole, pyrazine, purine, acridine, (iso)nicotinate, nicotinic acid, nicotinamide or derivative thereof. A polyether compound may be also present.
Patent MX-153675-A (MX)
Inventor: LEMMER HELMUT
IPC: H01F5/02
Filed: 1983-06-17
Abstract: 1. Coil bobbin for electromagnetically operated switching devices, consisting of at least one coil holder (1, 2; 24 to 27) made from plastics material and at least one coil winding (40, 41) located on the outside of the coil holder, in which case the coil holder comprises a hollow member open at both opposing end faces, of rectangular cross section and formed by rectangular side walls (3, 4; 5 to 8) and likewise rectangular flange edges (9 to 12) at the end faces of the hollow member projecting outwards at right angles to the side walls, which edges have dimensions such that they form the lateral boundary for the coil winding, characterised in that in a plane of division (13), which extends at right angles to the flange edges (9, 10, 11, 12) and through two opposing side walls (5, 6, 7, 8), the coil holder is divided into two symmetrical coil holder halves (1, 2), which are connected to each other in one piece by two flexible hinge strips (16, 17), which seen in the opened out position of the two coil holder halves (1, 2), are provided to extend exclusively between two opposing corners of the flange edges (9, 10; 11, 12) in the region of the plane of division (13) and that remaining design of the coil holder is arranged so that in the opened out position, the coil holder can be produced exclusively between two die-cast shaped parts.
Patent MX-159578-A (MX)
Inventor: MAY WILLIAMS GEORGE
IPC: A61K8/26
Filed: 1984-01-25
Abstract: Solid stick compositions comprising a long-chain fatty alcohol having from about 8 to about 18 carbon atoms in the chain, volatile silicone and C20 or longer chain alcohols at levels of from about 1% to about 3% of the total long-chain fatty alcohol present in the compositions. These solid sticks have improved strength and hardness without undue brittleness.
Patent NZ-216459-A (NZ)
Title: Infra red heater for glass top cooker
Inventor: MCWILLIAMS J A
IPC: H05B3/00
Filed: 1986-06-09
Abstract: An infra-red heater (1) for a glass ceramic top cooker comprises a dish containing a base layer of thermal insulating material. A peripheral wall of thermal insulating material extends around the periphery of the base layer and at least one infra-red lamp (3) extends across the base layer. A ballast device (5) is electrically connected in series with the infra-red lamp, for example in the form of a coil of bare resistance wire, and serves to reduce inrush current to the lamp. A thermal cut-out device (7) cuts off the supply of power to the infra-red lamp and to the ballast device (5) if the temperature of the glass ceramic cooking surface becomes excessive. The coil of bare resistance wire preferably has an electrical resistance which is approximately half the electrical resistance of the infra-red lamp at its operating temperature. The use of a ballast device (5) enables the infra-red lamp (3) to be used in conjunction with a cyclic energy regulator (9).
Patent NZ-221153-A (NZ)
Title: Azepine derivatives, and pharmaceutical compositions
Inventor: WEBER KARL-HEINZ
IPC: C07D333/78
Filed: 1987-07-22
Abstract: Hetrazepines of the formula <IMAGE>  in which A, Z, n, X, Y, R1, R2, R3 and R4 have the meaning mentioned in the description. The novel compounds are to be used for the treatment of pathological conditions and diseases in which PAF (platelet-activating factor) is involved.
Patent NZ-223085-A (NZ)
Title: Dental cement composition
Inventor: WALTON IAN GEOFFREY
IPC: A61K6/00
Filed: 1988-01-06
Abstract: The compositions of this invention posses both calcium hydroxide cement characteristics and light cure characteristics and hence strong bonds are likely to form with both the tooth and conventional filling materials. There is less likelihood that a filling may fall out of a cavity. The present invention provides a two component composition which comprises a first component comprising an ethylenically polymerizable compound which contains both a salicylate group and at least one acrylate, alkacrylate, acrylamide or alkacrylamide group and second component comprising calcium hydroxide or a suitable precursor to calcium hydroxide.
Patent NZ-231824-A (NZ)
Title: Alkylaromatic hydrocarbon oligomers and their use as lubricating basestocks or as additives
Inventor: FORBUS THOMAS REGINALD
IPC: C10N20/02
Filed: 1989-12-18
Abstract: Aromatic compounds are alkylated with C20-C1300 olefinic oligomers by contacting the oligomers and aromatic compounds with an acidic catalyst to produce novel alkylated aromatic hydrocarbon compositions useful as lubricant basestock and additives. The olefinic oligomers used as alkylating agents are prepared from 1-alkene oligomerization in contact with a reduced chromium oxide catalyst on silica support. In one embodiment, the aromatic compounds are alkylated with a mono-olefinic HVI-PAO dimer which is prepared as a product or by-product from 1-alkene oligomerization using reduced chromium oxide on solid support. The alkylated aromatic hydrocarbons retain the unique features of the alkylating olefinic oligomer and exhibit high viscosity index and low pour point. The novel alkylaromatic compositions show improved thermal stability; also, the compositions are useful as lubricant additives for improved antiwear properties, antioxidant and other properties.
Patent NZ-233521-A (NZ)
Title: 2-substituted saccharin derivatives, preparation and pharmaceutical compositions thereof
Inventor: DUNLAP RICHARD PAUL
IPC: C07D275/06
Filed: 1990-05-01
Abstract: Novel 2-substituted saccharin derivatives useful as proteolytic enzyme inhibitors, compositions containing the same for the treatment of degenerative diseases and method of use thereof.
Patent NZ-241636-A (NZ)
Title: Oxaaza heterocyclyl-substituted quaternary phosphonium derivatives and pharmaceutical compositions
Inventor: SUNG J LEE
IPC: C07F9/6533
Filed: 1992-02-18
Abstract: A new class of phosphines in which the phosphorous atom is bonded directly to the carbon of an oxazinone:   <IMAGE>   In addition to their anti-inflammatory activity, these phosphines are useful as intermediates in producing compounds where the phosphine is replaced by a benzylidine, compounds which have also been proven useful in the treatment of inflammation and other conditions associated with arthritis.
Patent NZ-242233-A (NZ)
Title: Medicaments containing micronised dihydro-4-(3,5-di-t-butyl-4-hydroxy benzylidene)-2-methyl-2h-1,2-oxazin-3(4h)-one
Inventor: SUNG J LEE
IPC: A61K31/535
Filed: 1992-04-03
Abstract: An anti-inflammatory composition in which the active ingredient is micronized to form an intimate admixture which can be administered orally.
Patent NZ-245585-A (NZ)
Title: 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates and pharmaceutical compositions thereof
Inventor: RANJIT CHIMANLAL DESAI
IPC: C07F9/6558
Filed: 1992-12-23
Abstract: Novel 4-R1-R2-R3-2-saccharinylmethyl, 4-R4-4-R5-6-R6-4,5,6,7-tetrahydro-2-saccharinylmethyl and 4,7-C-4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates of formulas I, II and IIA respectively <CHEM> are useful in the treatment of degenerative diseases, and compositions containing them, methods for using them to treat degenerative diseases, and processes for their preparation by reaction of the corresponding 2-halomethylsaccharins with a phosphate, phosphonate or phosphinic acidderivative.
Patent NZ-258815-A (NZ)
Title: Electronic ignition and fuel injection system, using top-dead-centre signal and flywheel tooth sensor
Inventor: IMBERG HANS
IPC: F02D41/02
Filed: 1993-12-14
Abstract: PCT No. PCT/AU93/00650 Sec. 371 Date Aug. 17, 1995 Sec. 102(e) Date Aug. 17, 1995 PCT Filed Dec. 14, 1993 PCT Pub. No. WO94/13949 PCT Pub. Date Jun. 23, 1994An electronic timing system for producing precise timing control signals to the fuel injectors and ignition coils of an internal combustion engine. The system includes a cylinder cycle marker circuit (16) for generating an engine cycle reference signal based on the detected operational position of the engine as indicated by a TDC signal and a fly wheel teeth (FWT) signal. The system also includes a cylinder sequencer (22) for controlling the sequence of combustion in respective cylinders of the engine responsive to the engine cycle reference signal. A multiplying circuit (14) is provided for multiplying the incoming FWT signal to produce a high resolution engine rotation signal which is a programmable integer multiple of the FWT signal. Injector and ignition timing control signals can be delayed by timers (24, 26) with a programmable delay specified in terms of an integer multiple of the multiplied FWT signal, and can therefore be precisely set in terms of  DEG  crank angle before TDC regardless of the engine speed. Furthermore, being angle referenced each programmable delay at least maintains the last calculated advance setting regardless of changes in engine speed.
Patent NZ-269845-A (NZ)
Title: Fungicidal granules; water dispersible granules comprising 3-chloro-n-(3-chloro-5-trifluoromethyl-2-pyridyl)-alpha,alpha, alpha-trifluoro-2,6-dinitro-p-toluidine as active component
Inventor: KIMURA TOKIYA
IPC: A01N43/40
Filed: 1994-08-10
Abstract: PCT No. PCT/JP94/01320 Sec. 371 Date Feb. 9, 1996 Sec. 102(e) Date Feb. 9, 1996 PCT Filed Aug. 10, 1994 PCT Pub. No. WO95/04460 PCT Pub. Date Feb. 16, 1995N-pyridyltoluidine-containing fungicidal water dispersible granule which comprises 3-chloro-N-(3-chloro-5-trifluoromethyl-2-pyridyl)- alpha , alpha , alpha -trifluoro-2,6-dinitro-p-toluidine as a fungicidal active component, a surfactant and a carrier, and of which a 1% water suspension is acescent.
Patent NZ-283876-A (NZ)
Title: Pyrimidinyl derivatives as interleukin inhibitors
Inventor: DOLLE ROLAND E
IPC: A61K38/00
Filed: 1995-03-29
Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein Y is a group of formula (a) and when R6 is OH, then Y can also be a group of formula (b), R5 is H or deuterium, R6 is OR8 or NHOH where R8 is independently H, alkyl or aralkyl, R3 and R4 are independently H, alkyl or aralkyl, R2 is H, alkyl, (CH2)0-4-cycloalkyl, a group of formula (c) or (d), aryl, heteroaryl, aralkyl, heteroaralkyl, (CH2)2-4-R10, n is 1-3, R10 is alkoxy, CH2F, CHF2, CF3, CF2CF3, OH, COOR11, CONR9R11 or NR9R11, R9 is independently H, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, CH2CH2O-alkyl and C(O)R12, R11 is independently H, alkyl, aryl, aralkyl, heteroaryl and heteroaralkyl, And when R9 and R11 are taken together, they can equal a five, six or seven membered ring of formula (e) where n is 1-3 and m is 0-1, R12 is alkyl, aryl, aralkyl, heteroaryl and heteroaralkyl, R7 is H, CH2F, CHR13O(CO)0-1-aryl, CHR13OP(O)(R14)R15, or a group of formula (f-i), wherein, R13 is H or alkyl, R14 is H, alkyl or aryl, R15 is H, alkyl or aryl, R16 is H, alkyl, aryl, heteroaryl, aralkyl or heteroaralkyl, R17 is H, alkyl, CF3, CF2CF3, aryl, heteroaryl, aralkyl, heteroaralkyl, COOR11 or CONR9R11, R18 is H, alkyl, CF3, CF2CF3, aryl, heteroaryl, aralkyl, heteroaralkyl, R1 is R19-R2, R19-R20, R19-R21, R19-NR9R11, wherein R19 is (CR3R4)0-4, R20 is a group of formula (j) or (k), where X=O, S, NR9, R21 is a group of formula (l) or (m), where n is 1-3, R22O, where R22 is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, R19-cycloalkyl, R19-R21, R23-R10, R23-R20, wherein R23 is (CR3R4)2-4, R9R11N or R24R11N where R24 is R19-cycloalkyl, R19-R21, R23-R10, R23-R20, CR3R4COOR11 and CR3CR4CONR9R11. The abovementioned compounds are useful for inhibiting interleukin-1beta and may me used to manufacture medicaments for the treatment of inflammatory and immune-based diseases of the lung, central nervous system and connective tissues.
Patent NZ-305062-A (NZ)
Title: A process for liquefying starch
Inventor: ANTRIM RICHARD L
IPC: C12P19/14
Filed: 1996-03-07
Abstract: According to the invention a method is provided for liquefying starch comprising the steps of treating the starch prior to or simultaneously with liquefying the starch to inactivate and/or remove the enzyme inhibiting composition present in the starch and form treated starch; adding  alpha -amylase to the treated starch; and reacting the treated starch for a time and at a temperature effective to liquefy the treated starch. Effective means to treat the starch include the addition of a phytate degrading enzyme and heat treatment, optionally followed by filtration or centrifugation, of granular starch or a starch solution.\!
Patent NZ-328346-A (NZ)
Title: An attachment to a gas driven nail gun for accommodating a washer with the nail
Inventor: HOWARD DOUGLAS JAMES
IPC: B25C7/00
Filed: 1998-08-25
Abstract: Applicator 5 is a cordless nail driving tool.  Member 6 is for manual placement of a washer so that a nail and washer (not shown) are driven together.
Patent NZ-328749-A (NZ)
Title: Carton flap folding method and apparatus
Inventor: EASTER WILLIAM M
IPC: B65B21/24
Filed: 1997-05-21
Abstract: carton flap folding apparatus includes a spaced, generally parallel, pair of knock-down arms (32) which are rotated in the direction of a path of travel (P) of groups of articles (G) to be packaged.  The knock-down arms (32) are rotated into engagement with at least one open flap (45) of a carton blank carried by a group of articles (G), at substantially the same speed as the speed of the group of articles.  The speed of the knock-down arms (32) is decreased with respect to the speed of the group of articles (G) prior to engaging the at least one open flap (45) of the carton blank, and increased with respect to the speed of the group of articles (G) for disengaging the knock-down arms (32) from the at least one hinged flap (45) of the carton blank.
Patent NZ-336398-A (NZ)
Title: A centrifuge apparatus with temperature control means
Inventor: HOLM NIELS ERIK
IPC: A61K35/14
Filed: 1998-01-08
Abstract: An apparatus is adapted to centrifuge and furthermore automatically handle a container (10) for separating a component, such as fibrin monomer, from plasma. The container (10) comprises a cylindrical member (11) and a piston (25) displaceable therein and comprising a tubular piston rod (12), which extends through the top wall. The piston (25) divides the cylindrical member (11) into a first chamber positioned above said piston (25) between said piston and said top wall and a second chamber positioned below said piston (25). The apparatus comprises a supporting turntable (1) with means for releasably retaining the cylindrical member (11), said supporting turntable being connected to a first activating means (5) for rotating the supporting turntable (1) with the container (10) about the central axis thereof. The apparatus comprises furthermore a rotatably journalled piston activating mechanism (13, 15, 16) adapted to activate the piston by means of a second activating means (21). A heat-emitting device (26, 27) is provided opposite the position of the cylindrical member (11) in the apparatus.
Patent NZ-502727-A (NZ)
Title: Expandable stent
Inventor: PENN IAN M
IPC: A61F2/91
Filed: 1998-07-08
Abstract: An expandable stent comprising a proximal end and a distal end in communication with one another, a tubular wall disposed between the proximal end and the distal end, the tubular wall having a longitudinal axis and a porous surface defined by a plurality of interconnected struts, the interconnected struts comprising a gradient of strut thickness from a first end to a second end of the tubular wall, the stent being expandable from a first, contracted position to a second, expanded position upon the application of a radially outward force on the stent. The stent is ideally suited for applications in which a tortuous pathway must be followed to the stenosis or blockage and in which high radial rigidity of the expanded stent is required - e.g., the treatment of ostial stenosis.
Patent NZ-503431-A (NZ)
Title: Methods of modulating serine/threonine protein kinase function, in particular RAF, with 5-azaquinoxaline-based compounds
Inventor: MCMAHON GERALD
IPC: A61K31/4985
Filed: 1998-10-05
Abstract: 5-azaquinoxaline-based compounds are useful for modulating the function of serine/threonine protein kinases, including RAF. The compounds are useful for treating cancers, a fibrotic discloser and conditions associated with an aberration in a signal transduction pathway characterised by an interaction between serine/threonine protein kinase and a natural binding partner. Of particular significance are compounds of formula (I). These compounds are synthesised by reacting 2-amino-6-chloro-3-nitropyridine with an alcohol or an amine in the presence of a catalyst, and reacting the resulting product with a reducing agent.
Patent NZ-503738-A (NZ)
Title: Aromatic C16-20-substituted tetrahydro prostaglandin F analogues useful as FP agonists
Inventor: DELONG MITCHELL ANTHONY
IPC: A61P19/10
Filed: 1998-09-04
Abstract: A compound having the structure below characterized in that R1 is CO2H, C(O)NHOH, CO2Rs, CH2OH, S(O)2Rs, C(O)NHR5, C(O)NHS(O)2R5, or tetrazole; characterized in that R5 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, aromatic ring, or heteroaromatic ring; R2 is H or lower alkyl; is NR6R7, OR8, SR9, S(O)R9, S(O)2R9, or F; characterized in that R6, R7, and R8 are independently selected from the group consisting of H, acyl, alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, aromatic ring, or heteroaromatic ring; and characterized in that Rg is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, aromatic ring, or heteroaromatic ring; R3 and R4 are independently H, alkyl, hydroxyalkyl, alkoxyalkyl, OR10, or SR10, except that both R3 and R4 are not H; characterized in that R10 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, aromatic ring, or heteroaromatic ring, R10 having from 1 to about 8 member atoms; Z is carbocyclic aliphatic ring, heterocyclic aliphatic ring, aromatic ring, or heteroaromatic ring; and any optical isomer, diastereomer, enantiomer of the above structure, or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof. The compounds are used to treat bone disorders.
Patent NZ-504202-A (NZ)
Title: Method of pest control using substituted 1,4-naphthoquinones
Inventor: HODGKINSON LESLIE CHARLES
IPC: A01N35/06
Filed: 2000-04-27
Abstract: A naphthoquinone of formula (I) is used in a method of combating acarids and insects wherein R1 and R2 are independently H or OH and R3 and R4 are independently H, halo or alkyl provided that when R1 and R2 are each H then R3 and R4 cannot be H.
Patent NZ-505655-A (NZ)
Title: A double-layered capsule with a soluble bismuth salt and an antibiotic in the external capsule and a second antibiotic and a potassium/sodium ATPase inhibitor in the internal capsule for therapy against Helicobacter pylori
Inventor: SANSO GIOVANNI
IPC: A61K33/24
Filed: 1998-12-14
Abstract: A pharmaceutical dosage form particularly suitable  for the   administration  of  active  principles   in   multiple therapies is disclosed.  The pharmaceutical dosage  form  is a  double  capsule  where in an internal capsule  is  placed inside  an external one.  Each internal and external capsule includes  one  or more active principles.  A double  capsule is  preferably used in triple or quadruple therapies against the  microorganisms Helicobacter pylori.  Advantages of this pharmaceutical  dosage form consist in  providing  a  simple posology   for  administration  of  two  and   more   active principles,  allowing the active principles to  activate  at the  right  intervals  of  time and  in  the  re-established quantities,  and  preventing  interactions  between   active principles.  It is preferred that the pharmaceutical  dosage form  has  an external capsule containing bismuth subcitrate and   metronidazole,  and  an  internal  capsule  containing tetracycline  and optionally omeprazole, which  is  used  in therapy for eradication of Helicobacter pylori.
Patent NZ-507862-A (NZ)
Title: Door operator controls door movement speeds according to force set commands
Inventor: FITZGIBBON JAMES J
IPC: E05F15/12
Filed: 1999-09-27
Abstract: The controller varies the pulse lengths of a pulse signal that is used to drive the motor of a door operator in either direction to thereby vary the motor speed.  The controller varies the pulse lengths for the motor driving the door in the up and down directions in response to respective force limits set by first and second force command setting devices.  By being able to set the start speeds of the motor the user can overcome installation variances such as stickiness or resistance to movement when the door is in the open or closed positions.
Patent NZ-507901-A (NZ)
Title: Isolated myelin basic protein (MBP) for treating mutliple sclerosis
Inventor: ARIMILLI SUBHASHINI
IPC: C07K19/00
Filed: 1999-05-05
Abstract: A myelin basic protein (MBP) peptide has an amino acid sequence of Phe-X-Lys-Asn-Ile-Val-X-X-X-Thr-X-X, wherein X is any amino acid. Preferably the sequence is Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-Pro-Pro. Also described are antibodies and a composition comprising an MHC Class II complex, capable of binding a T cell receptor, and a myelin basic protein peptide of the sequence Phe-X-Lys-R1-Ile-Val-X-X-X-Thr-X-X, wherein X is any amino acid and R1 is Asn or Gln. The complex consists of An MHC Class II polypeptide comprising an extracellular domain of an MHC Class II molecule sufficient to form an antigen binding pocket wherein the Class II component is encoded by an allele associated with an autoimmune disease directed to myelin basic protein and is soluble under physiology conditions in the absence of detergent or lipid. The composition and the peptide are useful in inhibiting a T-cell mediated immune response, preferably wherein the T-cell mediated immune response causes a pathology to the a neurological system i.e. multiple sclerosis.
Patent NZ-512309-A (NZ)
Title: Prion-free therapeutic formulations produced from somatic cells with an artificially altered prion protein (PrP) gene
Inventor: PRUNISER STANLEY B
IPC: A61K35/76
Filed: 1999-12-13
Abstract: A cell culture comprising host cells having their genome manipulated to; express a chemical or biological molecule useful in a therapeutic composition; and not express a PrP protein due to the alteration of any endogenous PrP sequences; and methods of their production.
Patent NZ-515356-A (NZ)
Title: Crystallised Fab'-epitope complex from the HIV-1 cross- neutralizing monoclonal antibody 2F5
Inventor: PAI EMIL F
IPC: C07K19/00
Filed: 2000-04-05
Abstract: The crystal structure of the Fab' fragment of Mab 2F5, a potent neutralizer of both laboratory strains and primary clinical isolates of most clades of HIV-1, both uncompleted and completed with the largely conserved peptide sequence ELDKWAS of the viral envelope protein gp41, has been elucidated and the characteristics of peptide-protein interactions determined. Having regard to such determination, the peptide-mimetics are constrained in the three-dimensional structure to provide an increased immunogenicity to the epitope sequence.